Drug evaluation: sapacitabine--an orally available antimetabolite in the treatment of cancer.
Cyclacel Pharmaceuticals, under license from Sankyo Co, is developing the prodrug sapacitabine for the potential treatment of cancer. Sankyo initiated phase I trials prior to Cyclacel's acquisition, and phase Ib trials are currently in progress.
Galmarini
Carlos M
CM
Université Claude Bernard Lyon 1, INSERM 590, 28 rue Laennec, 69373 Lyon, France. carlos.galmarini@recherche.univ-lyon1.fr
D000284:Administration, Oral; D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001087:Arabinonucleosides / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D017321:Clinical Trials, Phase I as Topic; D003596:Cytosine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D010330:Patents as Topic
D000964:Antimetabolites, Antineoplastic; D001087:Arabinonucleosides; D003596:Cytosine; C117959:sapacitabine